About aditx therapeutics inc. - ADTX
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.
ADTX At a Glance
Aditxt, Inc.
737 North Fifth Street
Richmond, Virginia 23219
| Phone | 1-650-870-1200 | Revenue | 645.18K | |
| Industry | Biotechnology | Net Income | -32,380,839.00 | |
| Sector | Health Technology | Employees | 47 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ADTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.107 |
| Price to Book Ratio | 0.545 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.788 |
| Enterprise Value to Sales | 31.179 |
| Total Debt to Enterprise Value | 0.906 |
ADTX Efficiency
| Revenue/Employee | 13,727.149 |
| Income Per Employee | -688,954.021 |
| Receivables Turnover | 0.11 |
| Total Asset Turnover | 0.023 |
ADTX Liquidity
| Current Ratio | 0.267 |
| Quick Ratio | 0.238 |
| Cash Ratio | 0.004 |
ADTX Profitability
| Gross Margin | -101.405 |
| Operating Margin | -4,039.583 |
| Pretax Margin | -5,020.405 |
| Net Margin | -5,018.916 |
| Return on Assets | -117.081 |
| Return on Equity | -304.579 |
| Return on Total Capital | -94.475 |
| Return on Invested Capital | -267.725 |
ADTX Capital Structure
| Total Debt to Total Equity | 113.463 |
| Total Debt to Total Capital | 53.153 |
| Total Debt to Total Assets | 40.867 |
| Long-Term Debt to Equity | 6.488 |
| Long-Term Debt to Total Capital | 3.039 |